Cyclophosphamide News and Research

RSS
Cyclophosphamide is a drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. It is also used to treat some types of kidney disease in children. Cyclophosphamide attaches to DNA in cells and may kill cancer cells. It is a type of alkylating agent. Also called CTX and Cytoxan.

Cyclophosphamide is a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.
Inherited traits and tumor mutations affect response to treatment of leukemia

Inherited traits and tumor mutations affect response to treatment of leukemia

Researchers turn fatal brain cancer into treatable disease for children

Researchers turn fatal brain cancer into treatable disease for children

Trial of Etanercept for Wegners's disease shows no benefit against the autoimmune condition

Trial of Etanercept for Wegners's disease shows no benefit against the autoimmune condition

Genasense shown to enhance the anti-lymphoma activity of Velcade and Rituxan

Genasense shown to enhance the anti-lymphoma activity of Velcade and Rituxan

Single dose phase I data on CG53135 for the prevention of oral mucositis

Single dose phase I data on CG53135 for the prevention of oral mucositis

Mycophenolate mofetil is effective for managing symptoms of the most common type of lupus

Mycophenolate mofetil is effective for managing symptoms of the most common type of lupus

A revolutionary approach to angiogenesis could make cancer treatment more effective at killing tumours

A revolutionary approach to angiogenesis could make cancer treatment more effective at killing tumours

Data suggests potential role of Quadramet in conjunction with chemotherapy for the treatment of acute myeloid leukemia

Data suggests potential role of Quadramet in conjunction with chemotherapy for the treatment of acute myeloid leukemia

Cell Therapeutics receives Fast Track Designation for Pixantrone, treatment for aggressive non-Hodgkin's lymphoma

Cell Therapeutics receives Fast Track Designation for Pixantrone, treatment for aggressive non-Hodgkin's lymphoma

Results from study of Rituxan in rheumatoid arthritis show promise

Results from study of Rituxan in rheumatoid arthritis show promise

Herceptin shows real promise in treatment of HER-2 positive breast disease

Herceptin shows real promise in treatment of HER-2 positive breast disease

Drug combo effective for advanced breast cancer

Drug combo effective for advanced breast cancer

Study of hematopoietic stem cell transplantation for severe, treatment-resistant lupus

Study of hematopoietic stem cell transplantation for severe, treatment-resistant lupus

Bladder cancer is the fourth most common cancer in men and the eighth most common in women

Bladder cancer is the fourth most common cancer in men and the eighth most common in women

First patient dosed with Tesmilifene in pivotal breast cancer study

First patient dosed with Tesmilifene in pivotal breast cancer study